Investor Presentaiton

The Need is Great. The Future is Bright. Patients' Unmet Medical Needs Drive Pfizer's Commitment and Investment in Immuno-Inflammatory Diseases BC Rheumatology 2 Enbrel etanercept XELJANZ [tofacitinib) Inflectra infliximab Gastroenterology XELJANZ [tofacitinib] Ixifi infliximab Inflectra™ infliximab Ixifi® infliximab Medical Dermatology eucrisa crisaborole ointment 2% Staquis crisaborole ointment 2% CIBINQO (abrocitinib) tablets Heterogeneity of patient population in immuno-inflammatory diseases requires a pipeline with multiple complementary mechanisms to address varying patient needs Pfizer *Pfizer has rights to Enbrel outside the US and Canada Confidential 6

View entire presentation